Anti-Mouse CD19 - DyLight® 550
| Code | Size | Price |
|---|
| LEI-C2110-50ug | 50 ug | £159.00 |
Quantity:
| LEI-C2110-100ug | 100 ug | £211.00 |
Quantity:
| LEI-C2110-200ug | 200 ug | £291.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rat
Antibody Isotype: IgG2a
Antibody Clonality: Monoclonal
Antibody Clone: 1D3
Regulatory Status: RUO
Target Species: Mouse
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 550
Format:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Fusion of NS-1 Myeloma cells with spleen cells
Long Description:
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.
NCBI Gene:
12478
Target:
CD19